Cathay Biotech Inc (688065) — Capital Reinvestment Ratio
Latest as of June 2025:
0.31x
Cathay Biotech Inc (688065) has a Capital Reinvestment Ratio of 0.31x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥251.82 Million) in capital expenditures (CN¥78.51 Million). See Cathay Biotech Inc (688065) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.31x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥251.82 Million
CNY
Capital Expenditures
CN¥78.51 Million
CNY
Data as of
Jun 2025
Most recent filing
Cathay Biotech Inc Capital Reinvestment Ratio (2017–2024)
This chart tracks Cathay Biotech Inc's Capital Reinvestment Ratio across 7 annual periods.
Annual Capital Reinvestment Ratio for Cathay Biotech Inc (2017–2024)
Year-by-year Capital Reinvestment Ratio for Cathay Biotech Inc from 2017 to 2024. For live market cap and broader valuation context, see 688065 company net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.03x | CN¥820.93 Million | CN¥843.31 Million | ▼ -62.7% |
| 2023 | 2.76x | CN¥569.45 Million | CN¥1.57 Billion | ▼ -47.2% |
| 2022 | 5.22x | CN¥803.67 Million | CN¥4.20 Billion | ▲ +110.5% |
| 2021 | 2.48x | CN¥594.18 Million | CN¥1.47 Billion | ▲ +67.5% |
| 2020 | 1.48x | CN¥514.96 Million | CN¥763.11 Million | ▲ +4.3% |
| 2019 | 1.42x | CN¥359.62 Million | CN¥511.14 Million | ▼ -92.4% |
| 2017 | 18.62x | CN¥53.45 Million | CN¥995.09 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow